UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): MARCH 13, 2006
----------------------
ENZO BIOCHEM, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
NEW YORK
--------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
001-09974 13-2866202
--------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
60 EXECUTIVE BOULEVARD
FARMINGDALE, NEW YORK 11735
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(631) 755-5500
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
(a) The following information, including the Exhibit attached hereto, is being
furnished pursuant to this Item 2.02 and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific
reference in such filing.
On March 13, 2006, Enzo Biochem, Inc., a New York corporation (the
"Company"), issued a press release discussing its financial results for its
second fiscal quarter ended January 31, 2006. A copy of the press release is
furnished as Exhibit 99.1 to this report.
ITEM 8.01. OTHER EVENTS.
On March 14, 2006, the Company issued a press release announcing that
its wholly owned subsidiary Enzo Therapeutics has initiated a Phase II clinical
trial to evaluate its immunomodulatory candidate drug EGS21 as a therapeutic for
managing Crohn's disease. A Phase I safety trial of EGS21 was successfully
concluded last year. The study is being conducted at Hebrew University Hadassah
Medical Center where subject enrollment is proceeding. The press release issued
by the Company announcing the foregoing is included as Exhibit 99.2 to this
Current Report on Form 8-K and is incorporated by reference in its entirety into
this Item 8.01.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
---------
Exhibit No. Description
---------- -----------
99.1 Press Release of Enzo Biochem, Inc., dated March 13,
2006, discussing financial results for second fiscal
quarter ended January 31, 2006.
99.2 Press Release of Enzo Biochem, Inc., dated March 14,
2006, announcing initiation of Phase II clinical trial.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
ENZO BIOCHEM, INC.
Date: March 13, 2006 By: /s/ Barry Weiner
------------------------------
Barry Weiner
President and Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
---------- -----------
99.1 Press Release of Enzo Biochem, Inc., dated March 13,
2006, discussing financial results for second fiscal
quarter ended January 31, 2006.
99.2 Press Release of Enzo Biochem, Inc., dated March 14,
2006, announcing initiation of Phase II clinical trial.